The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of article analysis by ChatGPT: Using a cohort of patients with EGFR mutation-positive non-small cell lung cancer treated with first-line osimertinib.
 
Michitoshi Yabe
No Relationships to Disclose
 
Hirotsugu Kenmotsu
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Loxo (Inst); Novartis (Inst)
 
Suguru Matsuda
No Relationships to Disclose
 
Meiko Morita
No Relationships to Disclose
 
Motoki Sekikawa
No Relationships to Disclose
 
Kosei Doshita
No Relationships to Disclose
 
Hiroaki Kodama
No Relationships to Disclose
 
Keita Miura
Honoraria - AstraZeneca; Chugai Pharma; MSD
 
Noboru Morikawa
No Relationships to Disclose
 
Iida Yuko
No Relationships to Disclose
 
Nobuaki Mamesaya
Honoraria - AstraZeneca Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Haruki Kobayashi
No Relationships to Disclose
 
Ryo Ko
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - MSD
 
Kazushige Wakuda
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akira Ono
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Janssen Research & Development (Inst)
 
Haruyasu Murakami
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma
 
Tateaki Naito
Honoraria - Ono Pharmaceutical
 
Toshiaki Takahashi
Honoraria - Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD K.K.; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K. (Inst); Pfizer (Inst)